8-K: Beyond Air Soars with 157% Revenue Growth

Beyond Air, Inc. reported a 157% increase in fiscal first-quarter revenue to $1.8 million, driven by strong LungFit PH adoption and international expansion, while reaffirming full-year fiscal 2026 revenue guidance.

Summary

• Revenues for the fiscal first quarter ended June 30, 2025, increased by 157% to $1.8 million, up from $0.7 million in the same period last year.
• Sequential revenue growth was approximately 50%, reaching $1.8 million compared to $1.2 million in the quarter ended March 31, 2025.
• The company achieved a gross profit of $0.2 million for the quarter, a significant improvement from a gross loss of $0.3 million in the prior year.
• Net loss attributed to common stockholders decreased to ($7.7) million, or ($1.53) per share, compared to a net loss of ($12.2) million, or ($5.32) per share, in the fiscal first quarter of 2024.
• Research and development expenses decreased by $2.9 million to $3.1 million, and selling, general and administrative expenses decreased by $2.5 million to $4.7 million.
• Beyond Air reaffirmed its revenue guidance for the full fiscal year 2026 (ending March 31, 2026) to be between $12 million and $16 million.
• The company was awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., covering over 4,350 member hospitals and health systems.
• A PMA supplement for the second-generation LungFit PH system was submitted to the U.S. FDA in June 2025.
• The U.S. FDA granted Orphan Drug Designation to BA-102 for Phelan-McDermid Syndrome, an investigational therapy in preclinical development for Autism Spectrum Disorder.
• A 1-for-20 reverse stock split became effective on July 14, 2025, to regain compliance with Nasdaq listing rules, which has since been achieved.
• Net cash burn for the quarter was $4.7 million, with cash, cash equivalents, and marketable securities totaling $6.5 million as of June 30, 2025.
• Total long-term debt outstanding was $11.6 million as of June 30, 2025, with debt repayment scheduled to begin in October 2026.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and significant improvements in profitability metrics (gross profit, reduced net loss). Key commercial and regulatory milestones were achieved, and Nasdaq compliance was regained. However, the company still operates at a net loss with a notable cash burn, and its cash position is relatively low compared to its debt, indicating potential future capital needs. The positive operational momentum outweighs the financial challenges for the quarter.

Positives

• Revenue increased by 157% year-over-year to $1.8 million for the fiscal quarter ended June 30, 2025, demonstrating strong market adoption of LungFit PH.
• Achieved sequential revenue growth of approximately 50% compared to the previous quarter.
• Transitioned from a gross loss of $0.3 million in the prior year to a gross profit of $0.2 million.
• Net loss significantly reduced to ($7.7) million from ($12.2) million in the same period last year.
• Reduced Research and Development expenses by $2.9 million and Selling, General and Administrative expenses by $2.5 million.
• Secured a national group purchasing agreement with Premier, Inc., expanding U.S. market reach to over 4,350 member hospitals.
• Accelerated international revenue through new distribution agreements across Europe, the Middle East, and Asia, reaching over 30 countries.
• Submitted a PMA supplement for the second-generation LungFit PH to the U.S. FDA.
• Received U.S. FDA Orphan Drug Designation for BA-102 for Phelan-McDermid Syndrome, advancing the NeuroNOS program.
• Regained compliance with Nasdaq listing rules following a 1-for-20 reverse stock split.

Negatives

• Continued to report a net loss of ($7.7) million for the fiscal quarter ended June 30, 2025.
• Experienced a net cash burn of $4.7 million during the quarter.
• Cash, cash equivalents, and marketable securities stood at $6.5 million as of June 30, 2025, while total long-term debt was $11.6 million.
• Other expense increased by $(1.0) million due to a prior period gain associated with the change in fair value of derivative liability.

Risks

• The ability to raise additional capital to fund operations and development.
• Uncertainty regarding the timing and results of future pre-clinical studies and clinical trials.
• Potential for regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, to delay or not grant approval for product candidates.
• The company's approach to discover and develop novel drugs is unproven and may not lead to efficacious or marketable products.
• Challenges in obtaining, maintaining, and protecting intellectual property utilized by products.
• Competition from other companies using similar technology or developing products for similar uses.
• Dependence on collaborators for certain aspects of development and commercialization.

Future Outlook

Beyond Air expects sustained double-digit sequential revenue growth and reaffirmed its full fiscal year 2026 revenue guidance of $12 million to $16 million. The company plans to progress its NeuroNOS program to a Phase 1 first-in-human clinical trial by the end of 2026, with data expected in 2027, and continues to advance its second-generation LungFit PH system through regulatory processes.

Management Comments

• We are driving strong market adoption of LungFit PH as we continue to break down barriers and expand our global distribution network.
• This momentum in our business resulted in strong sequential revenue growth of approximately 50%, to $1.8 million compared with $1.2 million for the March 31, 2025 quarter.
• Looking ahead, we expect the trajectory of our sales to support sustained double-digit sequential revenue growth and reaffirm our FY 2026 revenue guidance of $12 to $16 million.

Industry Context

Beyond Air operates in the medical device and biopharmaceutical sectors, specifically leveraging nitric oxide technology for respiratory illnesses, neurological disorders, and solid tumors. The company's focus on expanding its LungFit PH system's commercial reach through national group purchasing agreements and international distribution aligns with broader trends of increasing adoption of innovative medical technologies and global market penetration. Its pipeline development in areas like ASD and oncology positions it within high-growth therapeutic areas, though these are still in early clinical stages. The company's strategy to replace traditional NO cylinders with its LungFit system addresses operational efficiencies and safety concerns prevalent in hospital settings, potentially disrupting the existing market for therapeutic gases.

Comparison to Industry Standards

• The 157% year-over-year revenue growth for LungFit PH is exceptionally strong, indicating rapid market penetration for a commercial-stage medical device. This rate of growth often surpasses typical industry averages for established medical device companies, though it is more common for early-stage commercial products.
• The transition from a gross loss to a gross profit suggests improving economies of scale and potentially better pricing or cost management, which is a positive step towards industry-standard profitability for medical device sales.
• The reduction in R&D and SG&A expenses, while positive for the bottom line, should be monitored to ensure it does not impede future innovation or market expansion, especially compared to competitors who might be increasing investment in these areas.
• The national group purchasing agreement with Premier, Inc. is a significant milestone, comparable to similar agreements secured by leading medical device companies to streamline access to a vast network of hospitals and health systems, such as those held by major players like Medtronic or Philips for their respective device portfolios.
• The Orphan Drug Designation for BA-102 for Phelan-McDermid Syndrome is a regulatory achievement that provides market exclusivity and tax credits, a common strategy for biopharmaceutical companies developing treatments for rare diseases, similar to designations received by companies like Sarepta Therapeutics or BioMarin Pharmaceutical for their rare disease therapies.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved financial performance (reduced loss, gross profit), regained Nasdaq compliance, and positive outlook. However, continued net loss and cash burn could lead to future dilution if capital raises are necessary.
• Customers (Hospitals/Health Systems): Positive impact due to expanded access to LungFit PH through the Premier, Inc. agreement, potentially offering special pricing and terms.
• Employees: Positive impact from business growth and expansion, potentially leading to job stability or growth opportunities.
• Creditors: The company has $11.6 million in long-term debt with repayment starting October 2026. Improved financial performance and revenue trajectory could enhance confidence in future repayment ability.

Next Steps

• Continue driving market adoption and expanding global distribution network for LungFit PH.
• Await U.S. FDA decision on the PMA supplement for the second-generation LungFit PH.
• Progress the NeuroNOS program (BA-102) to a Phase 1 first-in-human clinical trial by the end of 2026.
• Anticipate data from the NeuroNOS Phase 1 clinical trial in 2027.
• Begin debt repayment in October 2026.
• Conduct Phase 1b trial for Beyond Cancer's solid tumor program (combination therapy).

Key Dates

Recommendation

Beyond Air's fiscal first-quarter results show impressive revenue growth and significant improvements in key financial metrics like gross profit and net loss, indicating strong commercial execution for LungFit PH and effective cost management. The national group purchasing agreement and international expansion are substantial catalysts for future growth. However, the company continues to operate at a net loss with a notable cash burn, and its cash position is relatively low compared to its long-term debt. While the operational momentum is positive, the financial runway and potential need for future capital raises introduce a degree of uncertainty. A 'hold' recommendation is appropriate as investors should monitor the company's ability to sustain its growth trajectory, manage its cash burn, and execute on its clinical pipeline while navigating its financial structure before considering a stronger position.

Keywords

Beyond Air, XAIR, LungFit PH, Nitric Oxide, Medical Device, Biopharmaceutical, Respiratory Illnesses, Autism Spectrum Disorder, Solid Tumors, PPHN, Orphan Drug Designation, SEC Filing, Financial Results, Q1 2026, Revenue Growth, Nasdaq Compliance, Clinical Trials, Healthcare Technology